RecruitingPhase 2NCT06223360
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
Sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Enrollment
406 participants
Start Date
Mar 28, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Eligibility
Min Age: 50 YearsMax Age: 89 Years
Inclusion Criteria11
- Aged 50 to 89 (inclusive) at screening
- Mild Cognitive Impairment (MCI) due to AD or Mild dementia due to AD according to workgroups of the Diagnostic Guidelines of the National Institute on Aging and Alzheimer's Association (NIA-AA)
- Mini-Mental State Examination (MMSE) score 20-30 inclusive at screening-. Montreal Cognitive Assessment score (MoCA) \< 26 at screening
- Clinical Dementia Rating (CDR) global score of 0.5 or 1 with memory score of greater or equal to 0.5 at screening
- Positive plasma AD biomarker signature
- Participants who are treated with FDA-approved acetylcholinesterase inhibitors (AchEI)and/or memantine will have to be on a stable dosage regimen for at least 3 months prior to screening.
- Participants must have a study partner who has frequent interaction with them (approximately \>3-4 times per week), will be available for all clinic visits in person or remotely, and can assist in compliance with study procedures.
- Female participants must be post-menopausal for at least one year or surgically sterile(bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months prior to screening.
- Fluent in English or Spanish to ensure compliance with cognitive testing and study visit procedures.
- Ambulatory, or able to walk with an assistive device.
- Provision of informed consent from the participant (or the participant's legally authorized representative (LAR) if unable to provide consent) and the study partner.
Exclusion Criteria12
- Significant neurological disorder other than AD (e.g. hypoxia, stroke, traumatic brain injury
- Significant neurodegenerative diseases, other than AD, and causes of dementias, Parkinson's disease and Huntington's disease, vascular dementia, CJD (Creutzfeldt-Jakob disease), LBD (Lewy Body dementia), PSP (Progressive Supranuclear Palsy), AIDS (Acquired Immunodeficiency Syndrome), or NPH (normal pressure hydrocephalus).
- Meeting Diagnostic Criteria for Possible AD according to workgroups of the Diagnostic Guidelines of the NIA-AA.
- A current diagnosis of uncontrolled Type I or Type II diabetes mellitus, as defined by Hemoglobin A1C (Hb A1C ≥ 8).
- A current active, uncontrolled seizure disorder.
- Diagnosis of cancer, except for those participants who have undergone potentially curative therapy with no evidence of recurrence for \> 5 years.
- History of alcoholism or substance abuse, current or within past 5 years.
- Previous exposure to Benfotiamine within past 3 months.
- Contraindication to MRI.
- Participation in another clinical trial for an investigational agent and having taken at least one dose of study drug, unless confirmed as having been on placebo, within 4 weeks prior to the baseline visit. The end of a previous investigational trial is defined as the date of the last dose of an investigational agent.
- Initiation of a monoclonal antibody treatment targeting brain amyloid within 6 months prior to the baseline visit.
- A disability that may prevent the patient from completing all study requirements e.g.,blindness, deafness, severe language difficulty).
Interventions
DRUGLow Dose Benfotiamine
300mg benfotiamine capsules (BID, twice a day)
DRUGHigh Dose Benfotiamine
600mg benfotiamine capsules (BID, twice a day)
DRUGPlacebo
Placebo capsules to mimic benfotiamine capsules (BID, twice a day)
Locations(47)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06223360
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT066577689 locations